# Page 1
Proposed inclusion of new products of Haffkine Biopharma Corporation in the office procurement policy to be made by government departments.
The Government of Maharashtra
Department of Industry, Energy and Labour,
GOVERNMENT DECISION NO.: MEET 2020/ PR No.68/ INDUSTRY-4
Madam Cama Road, Hutatma Rajguru Chowk,
Mantralaya, Mumbai- 400 032
Date: December 28, 2020
(1) Government Resolution, Department of Industry, Energy and Labour, No.Bhankhas-2014, No. 82/ Part-III/ Industry-4, dated 01st December, 2016.
Introduction: Department of Industry, Energy and Labour. As per the Government decision dated 01/12/2016, the procedure for procurement of offices by Government Departments has been approved. Also, the department. dated 24/08/2017 and dt. As per the Government decision dated 08/12/2017, the procedure for conducting procurement through Government e-Marketplace, a web portal developed by the Central Government, has been adopted. On this portal, the buyer department will provide the information to the buyers. Suggestions regarding adoption of the provisions of the Procurement Policy dated 01/12/2016. Purchase Policy No. 2.8 To review the provisions of the rule book. A high-level committee has been formed under the chairmanship of the Chief Secretary.
Accordingly, the Government has decided to revise the rules and regulations for the purchase of the proposed new products of Haffkine Biopharmaceutical Corporation. The matter of inclusion in Annexure-16 dated 01/12/2016 was under consideration of the Government.
GOVERNMENT DECISION: In accordance with paragraph 5.13 of the revised procurement policy of this Department dated 01.12.2016, reservation has been made for the purchase of self-produced drugs of Haffkine Biopharmaceutical Corporation Limited. The Department of Medical Education and Pharmaceuticals has proposed to include additional 9 products in Schedule 16. The proposed new 9 products will be self-produced through Haffkine Biopharma Corporation Limited and these quality medicines will be supplied to various government hospitals and primary health centres.
# Page 2
GOVERNMENT DECISION NO.: MEET 2020/ PR No.68/ INDUSTRY-4
In view of the above facts. Review Committee headed by Chief Secretary
Haffkine Drug Manufacturing Corporation pursuant to the agreement dated 02.11.2020
Limited to include the following 9 self-produced medicinal products in Annexure 16:
The government has approved the order.
9 new products.
Diclofenac sodium tablets (50mg) 6 Ofloxacin tablets (200 mg) 2 Atorvastatin tablets (20 mg) 7 Azithromycin tablets (250 mg)
3. Acyclovir tablets (20 mg) 8. Omeprazole capsules (20 mg) 4. Metformin tablets (500 mg) 9. Pantoprazole tablets (40 mg) 5. Olanzapine tablets (5 mg)
The following terms and conditions should be followed while purchasing the above 9 products through various Shaykik departments.
(a) The price and quality of the products should be competitive,
(b) The prices of these products should be in line with the National Pharmaceutical Pricing Authority (NPPA).
(c) Haffkine Biopharmaceuticals Limited shall endeavour to sell these products in the open market at 20-25 per cent of the production capacity.
(d) The decision shall be reviewed after three years.
# Page 3